Cited 0 times in
Effects of co-administration of metformin and evogliptin on cerebral infarct volume in the diabetic rat
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, SJ | - |
dc.contributor.author | Yoon, BS | - |
dc.contributor.author | Hong, JM | - |
dc.contributor.author | Joe, EH | - |
dc.contributor.author | Lee, JS | - |
dc.date.accessioned | 2023-02-27T07:12:45Z | - |
dc.date.available | 2023-02-27T07:12:45Z | - |
dc.date.issued | 2022 | - |
dc.identifier.issn | 0014-4886 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/24858 | - |
dc.description.abstract | Patients with diabetes suffer more severe ischemic stroke. A combination of metformin and dipeptidyl peptide-4 inhibitors is commonly prescribed to treat diabetes. Therefore, we aimed to determine if pretreatment with a combination of metformin and evogliptin, a dipeptidyl peptidase-4 inhibitor, could reduce cerebral infarct volume in rats with streptozotocin-induced diabetes. After confirming diabetes induction, the rats were treated with vehicle, evogliptin, metformin, or evogliptin/metformin combination for 30 days. Then, stroke was induced by transient middle cerebral artery occlusion (tMCAO). Infarct volume, oxidative stress, levels of methylglyoxal-modified protein, glucagon-like peptide-1 receptor (GLP-1R), AMPK, and Akt/PI3K pathway-related proteins, and post-stroke pancreatic islet cell volume were evaluated. Compared to vehicle, only the co-administration group had significantly reduced infarct volume from the effects of tMCAO; the regimen also improved glycemic control, whereas the individual treatments did not. Co-administration also significantly reduced methylglyoxal-modified protein level in the core of the brain cortex, and the expression of 4-HNE and 8-OHdG was reduced. Co-administration increased p-Akt levels in the ischemic core and mitigated the suppression of Bcl-2 expression. Plasma GLP-1 and dipeptidyl peptidase-4 levels and brain GLP-1R expression remained unaltered. In the pancreas, islet cell damage was reduced by co-administration. These results reveal that metformin and evogliptin co-administration ameliorates cerebral infarction associated with prolonged glycemic control and pancreatic beta cell sparing. Other potential protective mechanisms may be upregulation of insulin receptor signaling or reduction of methylglyoxal-induced neurotoxicity. The combination of metformin and evogliptin should be tested further for its potential against focal cerebral ischemia in diabetes patients. | - |
dc.language.iso | en | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Brain Chemistry | - |
dc.subject.MESH | Cerebral Infarction | - |
dc.subject.MESH | Cerebrovascular Circulation | - |
dc.subject.MESH | Diabetes Mellitus, Experimental | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Hypoglycemic Agents | - |
dc.subject.MESH | Infarction, Middle Cerebral Artery | - |
dc.subject.MESH | Insulin-Secreting Cells | - |
dc.subject.MESH | Magnetic Resonance Imaging | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Metformin | - |
dc.subject.MESH | Oxidative Stress | - |
dc.subject.MESH | Piperazines | - |
dc.subject.MESH | Rats | - |
dc.subject.MESH | Rats, Sprague-Dawley | - |
dc.subject.MESH | Reperfusion Injury | - |
dc.subject.MESH | Signal Transduction | - |
dc.subject.MESH | Stroke | - |
dc.title | Effects of co-administration of metformin and evogliptin on cerebral infarct volume in the diabetic rat | - |
dc.type | Article | - |
dc.identifier.pmid | 34780772 | - |
dc.subject.keyword | Diabetes mellitus | - |
dc.subject.keyword | Evogliptin | - |
dc.subject.keyword | Ischemic stroke | - |
dc.subject.keyword | Metformin | - |
dc.subject.keyword | Neuroprotection | - |
dc.contributor.affiliatedAuthor | Lee, SJ | - |
dc.contributor.affiliatedAuthor | Hong, JM | - |
dc.contributor.affiliatedAuthor | Joe, EH | - |
dc.contributor.affiliatedAuthor | Lee, JS | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.1016/j.expneurol.2021.113922 | - |
dc.citation.title | Experimental neurology | - |
dc.citation.volume | 348 | - |
dc.citation.date | 2022 | - |
dc.citation.startPage | 113922 | - |
dc.citation.endPage | 113922 | - |
dc.identifier.bibliographicCitation | Experimental neurology, 348. : 113922-113922, 2022 | - |
dc.embargo.liftdate | 9999-12-31 | - |
dc.embargo.terms | 9999-12-31 | - |
dc.identifier.eissn | 1090-2430 | - |
dc.relation.journalid | J000144886 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.